In Norway a large study has been performed upon patients with ischemic =
heart disease. They were treated with folic acid, vitamin B12 and/or =
vitamin B6. The result may be interesting to the ME population because =
some patients use methylcobalamin 10 mg subcutaneous every 2-4 days.=20
Cancer Incidence and Mortality After Treatment With Folic Acid and =
Vitamin B12
Marta Ebbing, MD; Kaare Harald B=C3=B8naa, MD, PhD; Ottar Nyg=C3=A5rd, =
MD, PhD; Egil Arnesen, MD; et al.
JAMA. 2009;302(19):2119-2126.=20
http://jama.ama-assn.org/cgi/content/short/302/19/2119?home
Citation:
"Conclusion Treatment with folic acid plus vitamin B12 was associated =
with increased cancer outcomes and all-cause mortality in patients with =
ischemic heart disease in Norway, where there is no folic acid =
fortification of foods."
The abstract of the article is inserted below.
/Kasper Ezelius, =C3=96rebro, Sweden
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D
=3D ME-f=C3=B6reningen: http://me-foreningen.se
=3D ME-information: http://me-cfs.se
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D
Cancer Incidence and Mortality After Treatment With Folic Acid and =
Vitamin B12
Marta Ebbing, MD; Kaare Harald B=C3=B8naa, MD, PhD; Ottar Nyg=C3=A5rd, =
MD, PhD; Egil Arnesen, MD; Per Magne Ueland, MD, PhD; Jan Erik =
Nordrehaug, MD, PhD; Knut Rasmussen, MD, PhD; Inger Nj=C3=B8lstad, MD, =
PhD; Helga Refsum, MD, PhD; Dennis W. Nilsen, MD, PhD; Aage Tverdal, =
PhD; Klaus Meyer, PhD; Stein Emil Vollset, MD, DrPH=20
JAMA. 2009;302(19):2119-2126.=20
Context Recently, concern has been raised about the safety of folic =
acid, particularly in relation to cancer risk.=20
Objective To evaluate effects of treatment with B vitamins on cancer =
outcomes and all-cause mortality in 2 randomized controlled trials.=20
Design, Setting, and Participants Combined analysis and extended =
follow-up of participants from 2 randomized, double-blind, =
placebo-controlled clinical trials (Norwegian Vitamin Trial and Western =
Norway B Vitamin Intervention Trial). A total of 6837 patients with =
ischemic heart disease were treated with B vitamins or placebo between =
1998 and 2005, and were followed up through December 31, 2007.=20
Interventions Oral treatment with folic acid (0.8 mg/d) plus vitamin =
B12 (0.4 mg/d) and vitamin B6 (40 mg/d) (n =3D 1708); folic acid (0.8 =
mg/d) plus vitamin B12 (0.4 mg/d) (n =3D 1703); vitamin B6 alone (40 =
mg/d) (n =3D 1705); or placebo (n =3D 1721).=20
Main Outcome Measures Cancer incidence, cancer mortality, and all-cause =
mortality.=20
Results During study treatment, median serum folate concentration =
increased more than 6-fold among participants given folic acid. After a =
median 39 months of treatment and an additional 38 months of posttrial =
observational follow-up, 341 participants (10.0%) who received folic =
acid plus vitamin B12 vs 288 participants (8.4%) who did not receive =
such treatment were diagnosed with cancer (hazard ratio [HR], 1.21; 95% =
confidence interval [CI], 1.03-1.41; P =3D .02). A total of 136 (4.0%) =
who received folic acid plus vitamin B12 vs 100 (2.9%) who did not =
receive such treatment died from cancer (HR, 1.38; 95% CI, 1.07-1.79; P =
=3D .01). A total of 548 patients (16.1%) who received folic acid plus =
vitamin B12 vs 473 (13.8%) who did not receive such treatment died from =
any cause (HR, 1.18; 95% CI, 1.04-1.33; P =3D .01). Results were mainly =
driven by increased lung cancer incidence in participants who received =
folic acid plus vitamin B12. Vitamin B6 treatment was not associated =
with any significant effects.=20
Conclusion Treatment with folic acid plus vitamin B12 was associated =
with increased cancer outcomes and all-cause mortality in patients with =
ischemic heart disease in Norway, where there is no folic acid =
fortification of foods.=20
Trial Registration clinicaltrials.gov Identifier: NCT00671346=20
Author Affiliations: Department of Heart Disease, Haukeland University =
Hospital, Bergen, Norway (Drs Ebbing, Nyg=C3=A5rd, and Nordrehaug); =
Department of Heart Disease, University Hospital of North Norway, =
Troms=C3=B8 (Drs B=C3=B8naa and Rasmussen); Departments of Community =
Medicine (Drs B=C3=B8naa, Arnesen, and Nj=C3=B8lstad) and Clinical =
Medicine (Dr Rasmussen), University of Troms=C3=B8, Troms=C3=B8, Norway; =
Institute of Medicine, University of Bergen and Haukeland University =
Hospital, Bergen, Norway (Drs Nyg=C3=A5rd, Ueland, Nordrehaug, and =
Nilsen); Institute of Basic Medical Sciences, University of Oslo, Oslo, =
Norway (Dr Refsum); Department of Physiology, Anatomy, and Genetics, =
University of Oxford, Oxford, England (Dr Refsum); Department of =
Cardiology, Stavanger University Hospital, Stavanger, Norway (Dr =
Nilsen); Division of Epidemiology, Norwegian Institute of Public Health, =
Oslo, Norway (Drs Tverdal and Vollset); Bevital AS, Bergen, Norway (Dr =
Meyer); and Department of Public Health and Primary Health Care, =
University of Bergen, Bergen, Norway (Dr Vollset).=20
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
Co-Cure Archives: http://listserv.nodak.edu/archives/co-cure.html
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
